Ovid Therapeutics Inc. (OVID) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, OVID scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 6 out of 20, reflecting ROIC of -28.5% and FCF yield of -7.67%; for an investor, this means the business is currently consuming cash rather than generating it, so any valuation depends on future program success rather than present earnings power. The whale/13F flow pillar scores 13 out of 20 for institutional accumulation and options positioning, which is the strongest pillar and represents a potential upside driver if institutional interest persists. The insider conviction pillar scores 3 out of 20 based on SEC Form 4 and Congressional PTR cluster flow, indicating weak insider-side signal. The macro regime fit pillar scores 7 out of 20 with a beta of 1.0 and sector sensitivity noted, meaning the stock is expected to move in line with the broader market without a defensive offset. The forensic balance sheet pillar scores 11 out of 20, citing an Altman Z-Score of 11.46, a Piotroski F-Score of 3 out of 9, and debt-to-equity of 0.5; the high Altman figure is a relative strength, while the low Piotroski score signals weak fundamental trend quality. Taken together, a prospective investor should weigh the institutional-flow strength against the negative cash generation and weak insider signal, and recognize that the rating reflects present financial vulnerability rather than a verdict on pipeline potential, which the source data does not quantify.

Ovid Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the market capitalization is $0.5B. The source data does not specify the company's products, customers, or revenue model beyond the reported financial figures.

Per the SEC financials, revenue rose from $0.4M in FY 2023 to $7.3M in FY 2025, while operating losses narrowed from $-59.3M to $-42.4M over the same span. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.5%. Per the Roarable RQD rating, the Altman Z-Score is 11.46 and the Piotroski F-Score is 3 out of 9. Cash declined from $26.3M in FY 2024 to $13.2M in FY 2025, and debt-to-equity is 0.5 per the rating inputs.

Per the recent news feed, headlines include a Yahoo Finance report on a fair value boost tied to analyst focus on OV329, a GuruFocus report on Wolfe Research initiating coverage with an outperform-type rating, and a Simply Wall St piece urging management to drive business growth carefully, which carries a GREEN catalyst light. Additional wire items include a TradingView listing, a Yahoo! Finance Canada seasonal-returns chart referencing a different company, and a report of the stock rising 3.71% to $2.23 as shares approached upper range call resistance. The butterfly supply-chain graph reports no supply chain links and no proprietary signals, so no upstream or downstream dependency is mapped.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology: Pharmaceutical Preparations classification. A prospective investor should note that pipeline-related second-order effects, such as partner dependencies or manufacturing relationships, are not resolved by the available data.

• What are the specific commercial products or pipeline programs generating the $7.3M in FY 2025 revenue, and what is their regulatory status?
• What are the valuation metrics (P/E, EV/EBITDA, EPS) given the absence of reported earnings per share?
• What is the composition of the debt position, since debt is listed as N/A in every reported period despite a debt-to-equity figure of 0.5?
• What is the company's cash runway given FY 2025 cash of $13.2M against FCF of $-38.3M?
• Who are the 13F institutional holders and insiders driving the whale-flow and insider pillar scores?